Pacira BioSciences (PCRX) Asset Writedowns and Impairment (2011 - 2022)
Pacira BioSciences' (PCRX) quarterly Asset Writedowns and Impairment came in at $16.1 million in Q4 2022, up 1052.43% quarter-over-quarter from $1.4 million in Q4 2011.
Pacira BioSciences (PCRX) Asset Writedowns and Impairment (2011 - 2022) Analysis & Trends
Pacira BioSciences' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $16.1 million for Q4 2022.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $16.1 million in Q4 2022; TTM through Dec 2024 was $16.1 million, a 7.98% decrease from a year earlier, with the FY2025 full-year figure at $11.0 million, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $16.1 million in Q4 2022 per PCRX's latest filing, from $1.4 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $16.1 million in Q4 2022 and bottomed at $16.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.20 Bn | 21.05 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.58 Bn | 12.15 Bn | 785.00 Mn |
| 10 | Pacira BioSciences | 1.07 Bn | 866.80 Mn | 140.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 16.13 Mn |
| Dec 31, 2022 | 16.13 Mn |
| Dec 31, 2011 | 1.40 Mn |
| Dec 31, 2011 | 1.40 Mn |